B cells from leukemic patients are relatively resistant to in-vitro EBV transformation.
Samples of peripheral blood mononuclear cells (PBMC) from normal donors or from leukemic patients were used to obtain Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL). Whereas the rate of transformation was around 85% with normal donors, it was only around 20% with leukemic patients. However no explanation for this resistance of B cells from leukemic patients to in-vitro EBV transformation could be found. Indeed no correlation exists between this EBV resistance and the age, sex, diagnosis or chemotherapeutic regimen. Furthermore no correlation is apparent between the percentage of B2+ cells, which should have EBV receptors, and the successful EBV transformation.
D001402:B-Lymphocytes / Q000382:microbiology*; D002472:Cell Transformation, Viral; D004854:Herpesvirus 4, Human; D006801:Humans; D007938:Leukemia / Q000097:blood*